Patent application number | Description | Published |
20080206777 | Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample. | 08-28-2008 |
20090047684 | Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan - The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample. | 02-19-2009 |
20090111124 | Kinase peptides and antibodies - The invention relates to novel kinase peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of a kinase-mediated disease, as well as for determining or monitoring the efficacy of treatment. | 04-30-2009 |
20090263819 | GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample. | 10-22-2009 |
20090298084 | GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF IRINOTECAN - The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample. | 12-03-2009 |
20100092473 | ANTI-PHOSPHO-AKT ANTIBODIES - The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed. | 04-15-2010 |
20110059464 | Biomarker Panel For Prediction Of Recurrent Colorectal Cancer - The present invention provides a biomarker panel predictive of whether colorectal cancer is likely to recur or metastasize in an afflicted patient. By identifying the likelihood of recurrence, a treatment provider may determine in advance those patients who would benefit from certain types of treatment. The present invention further provide methods of identifying gene and protein expression profiles associated with the likelihood of recurrence/metastasis of colorectal cancer in a patient sample. | 03-10-2011 |
20110189691 | Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample. | 08-04-2011 |
20120020978 | ANTIBODIES AGAINST FATTY ACID SYNTHASE - The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed. | 01-26-2012 |
20120094311 | GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample. | 04-19-2012 |
20120149594 | BIOMARKERS FOR PREDICTION OF BREAST CANCER - The invention provides gene expression profiles (GEPs), protein expression profiles (PEPs) as well as gene/protein expression profiles (GPEPs) and methods for using them to identify those patients who are likely to progress to breast cancer after detection of suspicious calcifications and/or fibrocystic disease by standard imaging techniques, e.g., mammography, MRI or ultrasound. The present invention further allows a treatment provider to identify those patients who are most likely to develop breast cancer to initiate and/or adjust treatment options for such patients accordingly. | 06-14-2012 |
20120165218 | METHOD AND ASSAY FOR DETERMINING FAS EXPRESSION - Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and/or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer. | 06-28-2012 |
20130095483 | PREDICTIVE BIOMARKERS FOR BREAST CANCER - The invention relates to compositions and methods for detecting, screening, diagnosing or determining the progression of, regression of and/or survival from a proliferative disease or condition, specifically breast cancer. The invention also provides new assays and kits for the staging or stratifying breast cancer patients or patients suspected of having breast cancer. | 04-18-2013 |
20130109587 | USP2A PEPTIDES AND ANTIBODIES | 05-02-2013 |
20130237449 | USP2A PEPTIDES AND ANTIBODIES - The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment. | 09-12-2013 |
20130237691 | USP2A PEPTIDES AND ANTIBODIES - The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment. | 09-12-2013 |
20130303744 | USP2A PEPTIDES AND ANTIBODIES - The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment. | 11-14-2013 |
20130338027 | Predictive Markers For Cancer and Metabolic Syndrome - Disclosed are predictive biomarkers and methods of use for the determination of insulin resistance and sensitivity, in addition to cardiovascular disease and risk associated with obesity. Methods for the stratification of patients along continuum of susceptibility to cardiometabolic risk, including prediction and progression to metabolic syndrome are also provided. | 12-19-2013 |
20140080737 | GENE EXPRESSION PROFILE FOR THERAPEUTIC RESPONSE TO VEGF INHIBITORS - The invention provides gene expression profiles (GEPs), protein expression profiles (PEPs) as well as gene/protein expression profiles (GPEPs) and methods for using them to identify metastatic breast cancer patients who are likely to respond to therapy with a VEGF inhibitor. The present invention allows a treatment provider to identify those patients who are most likely to respond to such treatment, and to initiate and/or adjust treatment options for such patients accordingly. | 03-20-2014 |
20140127708 | PREDICTIVE BIOMARKERS FOR PROSTATE CANCER - The invention relates to compositions and methods for detecting, screening, diagnosing or determining the progression of, regression of and/or survival from a proliferative disease or condition, specifically prostate cancer. The invention also provides new assays and kits for the staging or stratifying prostate cancer patients or patients suspected of having prostate cancer. | 05-08-2014 |
20140127714 | METHOD AND ASSAY FOR DETERMINING FAS EXPRESSION - Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and/or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer. | 05-08-2014 |
20140206018 | ANTIBODIES AGAINST FATTY ACID SYNTHASE - The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed. | 07-24-2014 |
20140364334 | CONGESTIVE HEART FAILURE BIOMARKERS - The invention provides gene and protein markers for cardiac disease and methods for using them to identify patients at risk for developing heart failure, or patients in an early stage of heart failure whose disease is likely to advance to a later stage. The present invention allows a treatment provider to identify those patients whose disease is most likely to develop and/or advance, and to initiate and/or adjust treatment options for such patients accordingly. | 12-11-2014 |
20140371087 | MIXED FORMAT MICROARRAYS - The invention provides methods, database and information management system for using mixed format microarrays to identify and validate biomarkers in target samples. The present invention provides highly accurate diagnostic assays and methods. | 12-18-2014 |
20150050665 | PREDICTIVE BIOMARKERS FOR BREAST CANCER - The invention relates to compositions and methods for detecting, screening, diagnosing or determining the progression of, regression of and/or survival from a proliferative disease or condition, specifically breast cancer. The invention also provides new assays and kits for the staging or stratifying breast cancer patients or patients suspected of having breast cancer. | 02-19-2015 |